Jolley Asset Management’s Zimmer Biomet ZBH Stock Holding History

Jolley Asset Management’s Portfolio ZBH Stock Details ZBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-41	Closed	-$4K	–	161
2018 Q2	$4K	Hold	41	–	–	﹤0.01%	162
2018 Q1	$4K	Buy	+41	New	+$4.76K	﹤0.01%	173
2014 Q2	–	Sell	-16	Closed	-$2K	–	129
2014 Q1	$2K	Hold	16	–	–	﹤0.01%	120
2013 Q4	$1K	Buy	+16	New	+$1.39K	﹤0.01%	126

Other funds holding ZBH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Longview Partners St Peter Port, Guernsey $7.06B AUM 3.43% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Nordea Investment Management Stockholm, Sweden $107B AUM 24.58% 1-Year Est. Return

Jolley Asset Management's ZBH Position: Q3 2018 in Review

Jolley Asset Management sold out of Zimmer Biomet (ZBH) in Q3 2018, closing a stake of 41 shares — an estimated $4K sold.

Jolley Asset Management first reported a position in ZBH in Q4 2013 and held it in 4 quarters. The position peaked at $4K in Q2 2018. 891 funds tracked by Wall St. Rank hold ZBH as of Q3 2018.

Jolley Asset Management reported no remaining Zimmer Biomet position as of Q3 2018 after selling out during the quarter.
Jolley Asset Management sold 41 Zimmer Biomet shares in Q3 2018, an estimated $4K.
Jolley Asset Management first reported a position in Zimmer Biomet in Q4 2013 and held it in 4 quarters.
Jolley Asset Management's Zimmer Biomet position peaked at $4K in Q2 2018.
891 funds tracked by Wall St. Rank held Zimmer Biomet as of Q3 2018.

Based on Jolley Asset Management's 13F filing for Q3 2018, filed 18 Oct 2018.